Sonoma Pharmaceuticals (SNOA) Rating Increased to Buy at Zacks Investment Research

Sonoma Pharmaceuticals (NASDAQ:SNOA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Friday. The firm currently has a $5.75 target price on the stock. Zacks Investment Research‘s price target would indicate a potential upside of 11.22% from the stock’s current price.

According to Zacks, “Sonoma Pharmaceuticals operates as a pharmaceutical company. It develops and markets solutions for the treatment of dermatological conditions, animal health and advanced tissue care. The company operates primarily in United States, Latin America and Europe. Sonoma Pharmaceuticals formerly known as Oculus Innovative Sciences and is headquatered in Petaluma, California. “

Other research analysts also recently issued research reports about the stock. Maxim Group set a $11.00 price target on shares of Sonoma Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, November 17th. Benchmark assumed coverage on shares of Sonoma Pharmaceuticals in a research note on Thursday, December 28th. They issued a “speculative buy” rating and a $10.00 price target on the stock.

Shares of Sonoma Pharmaceuticals (NASDAQ:SNOA) remained flat at $$5.17 on Friday. 7,400 shares of the company’s stock traded hands, compared to its average volume of 28,575. Sonoma Pharmaceuticals has a 12-month low of $4.16 and a 12-month high of $8.25. The firm has a market cap of $23.61, a PE ratio of -2.60 and a beta of 1.19. The company has a quick ratio of 4.56, a current ratio of 5.37 and a debt-to-equity ratio of 0.01.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last posted its quarterly earnings results on Thursday, November 9th. The company reported ($0.67) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.75) by $0.08. Sonoma Pharmaceuticals had a net margin of 47.68% and a negative return on equity of 43.23%. analysts expect that Sonoma Pharmaceuticals will post -2.71 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.com-unik.info/2018/01/19/sonoma-pharmaceuticals-snoa-rating-increased-to-buy-at-zacks-investment-research.html.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.

Get a free copy of the Zacks research report on Sonoma Pharmaceuticals (SNOA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit